ZyVersa Therapeutics' CEO, Stephen C. Glover Invited Speaker at the H.C. Wainwright 23rd Annual Global Investment Conference, September 13-15, 2021
ZyVersa is well positioned in the rapidly emerging inflammasome space with a highly differentiated inflammasome ASC inhibitor, IC 100, which has potential to treat a broad range of inflammatory diseases
ZyVersa's pipeline includes VAR 200, a phase 2a-ready first-in-class cholesterol efflux mediator for treatment of orphan renal disease, FSGS, and other glomerular conditions
WESTON, Fla., Sept. 7, 2021 /PRNewswire/ -- ZyVersa Therapeutics, Inc. (ZyVersa), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, is pleased to announce that Stephen C. Glover, ZyVersa's Co-Founder, Chief Executive Officer, and Chairman, is an invited speaker at the H.C. Wainwright 23rd Annual Global Investment Conference, being held virtually September 13-15, 2021. For conference details, Click Here.
Mr. Glover's presentation will highlight progress in advancing development of ZyVersa's inflammasome ASC inhibitor IC 100, and Phase 2a-ready VAR 200 for orphan renal disease, FSGS.
Mr. Glover's presentation will be available to registered conference attendees for on-demand viewing beginning Monday, September 13, 2021, at 7:00 AM Eastern.
To learn more about ZyVersa and its novel inflammasome inhibitor IC 100, or its phase 2a-ready cholesterol efflux mediator for renal disease, please schedule a 1 on 1 virtual meeting with ZyVersa using the conference portal.
About ZyVersa Therapeutics, Inc.
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have significant unmet medical needs. Our development pipeline includes a novel inflammasome ASC inhibitor with potential to treat multiple inflammatory diseases, and phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of a rare kidney disease, focal segmental glomerulosclerosis (FSGS) and other glomerular conditions. For more information, please visit www.zyversa.com.
SOURCE ZyVersa Therapeutics, Inc.
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article